Company
Anteris Technologies Pty Ltd
ASX:AVR
Anteris Technologies Pty Ltd is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
133 stories · page 4 of 7
Anteris Technologies boosted by $1.6 million R&D tax incentive refund
The Australian Government’s Research and Development Tax Incentive claim confirms Anteris’ significant and ongoing commitment to invest in, research and develop its structural heart technologies.
Anteris Technologies preliminary results show restoration of pre-disease blood flow compared to competing technologies
When current generation competing valve technologies were compared to the healthy aortic valve, they demonstrated statistically significant worse flow.
Anteris Technologies hosts Australian interventional cardiology experts at 3D tissue design facility in Perth
The company intends to partner with the clinicians to commercialise its DurAVR™ Transcatheter Heart Valve system, as well as to refine its clinical roadmap while also improving investor engagement.
Anteris Technologies' transcatheter heart valve continues to demonstrate its potential
Anteris’ mission is simple: to build a heart valve that lasts longer and works better than existing solutions. Now, with a fully realised product under its wing, the healthcare stock is working towards Food and Drug Administration clearance
Anteris Technologies appoints highly experienced doctor to help accelerate and further validate DurAVR™
New Anteris Global Medical Advisory Board member Dr Martin Leon MD will help accelerate the company's work in heart health treatment.
Anteris Technologies' heart valve technology continues to demonstrate improvement in blood flow and quality-of-life markers
“Its remarkable flow characteristics are as close to a normal human aortic valve as we have seen, a testament to the unique 3D tissue design,” chief medical officer Dr Chris Meduri said.
Anteris Technologies higher as six-month follow up shows 86% improvement in haemodynamics
The six-minute walk test, a key well-being marker, improved 46% since baseline and a further 21% between three and six months, demonstrating how much more active and fit patients can become when implanted with the DurAVR™ valve.
Anteris Technologies completes treatment of second cohort in first-in-human study for transcatheter heart valve system
“We are thrilled with the ongoing progress and the veracity of the results so far. The whole team including the treating physicians are excited by the results so far,” says CEO Wayne Paterson.